Enterprise Therapeutics, a UK-based life sciences firm targeting lung and mucus conditions, has closed its series A round at £4m ($6.3m).
The Sussex University spin-out previously raised £1.6m in February 2015 from life sciences investor Epidarex, which topped up its investment in the round by £400,000 along with Imperial Innovations, the technology transfer office of Imperial College London, which provided the additional £2m.
Enterprise Therapeutics, founded in May 2014, is seeking to develop therapies which target the causes of respiratory disease pathology and progression in cystic fibrosis, chronic obstructive pulmonary disease, and severe asthma.
Martin Gosling, chief scientific officer at Enterprise Therapeutics, said: “We are extremely excited to have secured additional funding from experienced and enabling partners who will help us to shape and grow our company.”
